Pancreatic cancer study failure cripples a Merrimack drug, forcing a coup de grâce and pipeline retreat
Eighteen months after Merrimack $MACK restructured, selling off its one marketed drug, switching out CEOs and circling the wagons around three key cancer drugs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
